A Phase I/II Dose Escalation study of the tumor-targeting human L19-IL2 monoclonal antibody-cytokine fusion protein in combination with Dacarbazine for patients with metastatic melanoma.
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 10 Nov 2016
At a glance
- Drugs L19-IL2 fusion protein (Primary) ; Dacarbazine
- Indications Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Philogen
- 27 Oct 2016 Planned End Date changed from 1 Dec 2016 to 1 Jun 2017.
- 05 Oct 2016 Planned End Date changed from 1 Aug 2016 to 1 Dec 2016.
- 05 Oct 2016 Status changed from recruiting to active, no longer recruiting.